Sign In
Buy OPORF
$0.350
+0 (+0%)
At Close: Jun 03, 2026
City broker eyes turning point as hVIVO posts stronger than anticipated update
10:29am, Thursday, 29'th Jan 2026
After hVIVO PLC (AIM:HVO) reported annual revenue of £46.7 million, in line with market expectations, City brokers were assessing whether the company is turning a corner after a difficult year. Br
hVIVO cheers stronger-than-expected delivery in 2025
03:40am, Thursday, 29'th Jan 2026
hVIVO PLC (AIM:HVO) told investors it expects to report revenue of approximately £46.7 million for the year, ended 31 December, in line with market expectations. Earnings (adjusted EBITDA) margin
hVIVO appoints Richard Cotton as non-executive director
03:33am, Thursday, 18'th Dec 2025
hVIVO PLC (AIM:HVO) has appointed Richard Cotton as an independent non-executive director with immediate effect. Cotton will also take on the role of chair of the audit committee and become a member o
Broker backs hVIVO 2026 rebound
05:48am, Friday, 12'th Dec 2025
Shore Capital thinks hVIVO PLC (AIM:HVO) shares are worth far more than the market price, despite a bruising year for the stock. The broker has reiterated its Buy rating and set a fair value of 25p a
hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement"
11:17am, Thursday, 27'th Nov 2025
Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a moment of reflected glory. Peel Hunt's analysts highlight that Cidara's lead antiviral, CD388, adva
hVIVO hails $9.2 billion Cidara takeover after key trial wins
02:57am, Thursday, 27'th Nov 2025
hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biotech agreed to be bought by MSD in a deal worth about $9.2 billion, saying the takeover highlights
hVIVO's German arm lands more than £5m in new trial work
02:33am, Thursday, 20'th Nov 2025
hVIVO PLC (AIM:HVO) has picked up more than £5 million in fresh contracts at its German business, giving the clinical research group a firmer footing as it heads towards next year. The London-listed
hVIVO expands human challenge study portfolio - ICYMI
03:43am, Sunday, 16'th Nov 2025
hVIVO PLC (AIM:HVO) chief scientific officer Andrew Catchpole talked with Proactive about the company's latest developments in human challenge models across multiple viral pathogens. Catchpole explai
hVIVO unveils new virus models in push for faster vaccine development
02:38am, Tuesday, 11'th Nov 2025
hVIVO PLC (AIM:HVO) has revealed successful early data on three new virus challenge models, including a first-of-its-kind human metapneumovirus (hMPV) model, aimed at speeding up the development of v
hVIVO CEO on growth plans and human challenge trials - ICYMI
02:51am, Saturday, 27'th Sep 2025
hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo' Khan talked with Proactive about the company's unaudited results for the first half of 2025 and its outlook for the remainder of the year. Khan explain
hVIVO steadies outlook as diversification offsets slower growth
06:45am, Tuesday, 23'rd Sep 2025
hVIVO PLC's (AIM:HVO) half-year results came in much as expected, with revenue of £24.2 million and cash of £23.3 million. The company reaffirmed full-year guidance of £47 million revenue and a sm
HVivo trading in line with expectations with early success in diversification strategy
03:26am, Tuesday, 23'rd Sep 2025
Human challenge clinical trial specialist hVIVO PLC (AIM:HVO) said it is trading in line with expectations for the year and remains on course for growth in 2026. In the first half of the year, reven
hVIVO appoints former Clinigen boss as chair
02:27am, Monday, 01'st Sep 2025
hVIVO PLC (AIM:HVO), the London-listed pharmaceutical research company, has named Shaun Chilton as its new chair, bringing in an industry veteran with more than three decades of experience. Chilton, w
hVIVO to appoints Shaun Chilton as new chair
02:46am, Tuesday, 29'th Jul 2025
hVIVO PLC (AIM:HVO), the contract research group specialising in human challenge clinical trials, said it plans to appoint Shaun Chilton as its new chair. He brings more than 30 years' experience in
hVIVO eyes 2026 growth after H1 update - ICYMI
09:04am, Saturday, 26'th Jul 2025
hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo' Khan talked with Proactive about the company's trading update for the first half of 2025 and shared insights into its outlook and operational progress.
